

# Natalie Danziger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8446240/publications.pdf>

Version: 2024-02-01

60  
papers

342  
citations

933447

10  
h-index

940533

16  
g-index

60  
all docs

60  
docs citations

60  
times ranked

536  
citing authors

#	ARTICLE	IF	CITATIONS
1	A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. <i>Modern Pathology</i> , 2021, 34, 252-263.	5.5	78
2	Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer. <i>Cancer Medicine</i> , 2021, 10, 53-61.	2.8	39
3	Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets. <i>JCO Precision Oncology</i> , 2020, 4, 647-661.	3.0	21
4	Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. <i>Oncologist</i> , 2020, 25, 943-953.	3.7	19
5	Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. <i>Modern Pathology</i> , 2021, 34, 1425-1433.	5.5	19
6	Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors. <i>Frontiers in Neurology</i> , 2020, 11, 544680.	2.4	16
7	Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. <i>Oncologist</i> , 2021, 26, 835-844.	3.7	16
8	Patient-matched tissue and liquid biopsies identify shared and acquired genomic alterations in breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1050-1050.	1.6	15
9	Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases. <i>International Journal of Cancer</i> , 2021, 148, 1778-1788.	5.1	14
10	Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. <i>Pathology and Oncology Research</i> , 2021, 27, 592997.	1.9	11
11	IDH1 and IDH2 Driven Intrahepatic Cholangiocarcinoma (IHCC): A comprehensive genomic and immune profiling study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4009-4009.	1.6	11
12	Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. <i>JCO Precision Oncology</i> , 2022, , .	3.0	10
13	Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. <i>Cancers</i> , 2021, 13, 3312.	3.7	9
14	Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100100.	1.1	8
15	Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 731.e1-731.e15.	1.6	7
16	FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab017.	0.7	6
17	Clinical, histopathologic, and molecular profiles of PRKAR1A-inactivated melanocytic neoplasms. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1069-1071.	1.2	5
18	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. <i>Cancer</i> , 2021, 127, 4557-4564.	4.1	5

#	ARTICLE	IF	CITATIONS
19	Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma. JCO Precision Oncology, 2021, 5, 1013-1023.	3.0	3
20	Differential genomic landscape of clinically advanced/metastatic chordomas (mChor) based on primary tumor site.. Journal of Clinical Oncology, 2020, 38, 11521-11521.	1.6	3
21	Acid-Based Decalcification Methods Compromise Genomic Profiling from DNA and RNA. Blood, 2019, 134, 4659-4659.	1.4	3
22	Genomic landscape of <i>CDK12</i> mutated metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 165-165.	1.6	2
23	Clinically advanced penile (pSCC) and male urethral (uSCC) squamous cell carcinoma: A comparative genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 2-2.	1.6	2
24	Sarcomatoid (srcRCC) versus clear cell (ccRCC) renal cell carcinoma: A comparative comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 349-349.	1.6	2
25	Comprehensive Genomic Profiling of 104 Rare Histiocytic and Dendritic Cell Neoplasms Reveals Shared and Distinct Targetable Genomic Alterations. Blood, 2019, 134, 2541-2541.	1.4	2
26	Comprehensive genomic profiling (CGP) in patients with relapsed/refractory germ cell tumors (GCT).. Journal of Clinical Oncology, 2020, 38, e17053-e17053.	1.6	2
27	Landscape of fibroblast growth factor receptor ( <i>FGFR</i> ) genomic alterations (GA) in urothelial bladder cancer (UBC).. Journal of Clinical Oncology, 2022, 40, 4568-4568.	1.6	2
28	Novel synthetic lethality (SL) anti-cancer drug target in urothelial bladder cancer (UCB) based on MTAP genomic loss: Incidence and correlations in standard of care (SOC).. Journal of Clinical Oncology, 2021, 39, 485-485.	1.6	1
29	Genomic landscape of <i>MSH6</i> -mutated clinically advanced castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5062-5062.	1.6	1
30	Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 3130-3130.	1.6	1
31	Primary tumor (p-bx) versus metastatic tumor (m-bx) tissue versus liquid biopsy (lb) in intrahepatic cholangiocarcinoma (IHCC): A comparative comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 4579-4579.	1.6	1
32	Increased tumor purity and improved biomarker detection using precision needle punch enrichment of pathology specimen paraffin blocks: Method validation and implementation in a prospective clinical trial.. Journal of Clinical Oncology, 2020, 38, 3622-3622.	1.6	1
33	Comprehensive genomic profiling (CGP) of histologic subtypes of urethral carcinomas (UrthCa).. Journal of Clinical Oncology, 2020, 38, 5087-5087.	1.6	1
34	Clinically aggressive malignancies associated with <i>STK11</i> germline mutations ( <i>STK11</i> GCa): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 3558-3558.	1.6	1
35	Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase ( <i>MTAP</i> ) genomic loss ( <i>MTAP</i> loss).. Journal of Clinical Oncology, 2022, 40, 604-604.	1.6	1
36	Abstract PD14-09: APOBEC signature, clinical characteristics, and outcome in hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer (BC) patients (pts) in real-world data (RWD). Cancer Research, 2022, 82, PD14-09-PD14-09.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Landscape of homologous recombination reversion mutations in pancreaticobiliary malignancies.. Journal of Clinical Oncology, 2022, 40, 4156-4156.	1.6	1
38	Association of <i>RB1</i> mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2022, 40, 5063-5063.	1.6	1
39	Landscape of homologous recombination reversion mutations in gynecologic malignancies.. Journal of Clinical Oncology, 2022, 40, 5576-5576.	1.6	1
40	In search of novel synthetic lethality anti-cancer drug targets in intrahepatic cholangiocarcinoma: MTAP genomic loss.. Journal of Clinical Oncology, 2021, 39, 337-337.	1.6	0
41	HHV-8 positive clinically advanced castrate-resistant prostate cancer (mCRPC): A potentially distinct molecular subset.. Journal of Clinical Oncology, 2021, 39, 163-163.	1.6	0
42	HPV-16 positive clinically advanced squamous cell carcinoma of the urinary bladder (mBSCC): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 481-481.	1.6	0
43	Comprehensive genomic profiling (CGP) in patients with relapsed/refractory germ cell tumors (GCT).. Journal of Clinical Oncology, 2021, 39, 388-388.	1.6	0
44	Genomic landscape of non-small cell lung cancer (NSCLC) with methylthioadenosine phosphorylase ( <i>MTAP</i> ) deletion.. Journal of Clinical Oncology, 2021, 39, 9116-9116.	1.6	0
45	Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype.. Journal of Clinical Oncology, 2021, 39, 8555-8555.	1.6	0
46	Comprehensive genomic profiling (CGP) of 275 male breast cancer (BC) tissue (TBx) and liquid (LBx) biopsies: Comparative analysis to a female cohort (FBC) and therapeutic considerations.. Journal of Clinical Oncology, 2021, 39, 539-539.	1.6	0
47	Contrasting genomic profiles in post-systemic treatment metastatic sites (MET), pretreatment primary tumors (PT), and liquid biopsies (LB) of clinically advanced prostate cancer (PC).. Journal of Clinical Oncology, 2020, 38, 5534-5534.	1.6	0
48	Acquired <i>RB1</i> mutations in estrogen receptor-positive (ER+) clinically advanced and metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2020, 38, 1053-1053.	1.6	0
49	Primary adult retroperitoneal sarcoma (RS): Comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 11541-11541.	1.6	0
50	Clinically advanced renal cell carcinoma (RCC) and renal sarcoma (RSC) in young patients: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 5066-5066.	1.6	0
51	Comprehensive genomic profiling (CGP) of fibrolamellar oncocytic hepatoma (FLO) and conventional hepatocellular carcinomas (HCC): An observational study.. Journal of Clinical Oncology, 2022, 40, 474-474.	1.6	0
52	Expanding the use of targeted therapy for urothelial bladder cancer (UBC): Non- <i>FGFR3</i> receptor tyrosine kinase (RTK) gene rearrangements (ReAr) and fusions (fus).. Journal of Clinical Oncology, 2022, 40, 550-550.	1.6	0
53	Association of <i>RB1</i> mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2022, 40, 156-156.	1.6	0
54	Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.. Journal of Clinical Oncology, 2022, 40, 563-563.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (<i>MTAP</i>) genomic loss.. Journal of Clinical Oncology, 2022, 40, 164-164.	1.6	0
56	Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with clear cell RCC (ccRCC): Impact of <i>FLCN</i> genomic alteration (GA) status.. Journal of Clinical Oncology, 2022, 40, 292-292.	1.6	0
57	Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study.. Journal of Clinical Oncology, 2022, 40, 5596-5596.	1.6	0
58	Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with non-chromophobe RCC (nonchrRCC): Impact of <i>FLCN</i> genomic alteration (GA) status.. Journal of Clinical Oncology, 2022, 40, 4550-4550.	1.6	0
59	Targetable genomic mutations in young women with advanced breast cancer.. Journal of Clinical Oncology, 2022, 40, 1027-1027.	1.6	0
60	Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UCB) genomic alteration (GA) profile.. Journal of Clinical Oncology, 2022, 40, e16535-e16535.	1.6	0